NCT04988867View on ClinicalTrials.gov

An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 22, 2021

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Rett Syndrome
Interventions
DRUG

Trofinetide

Trofinetide solution of 10-30 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)

Trial Locations (7)

35233

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

55101

Gillette Children's Hospital, Saint Paul

60612

Rush University Medical Center, Chicago

63110

Washington University, St Louis

80045

Children's Hospital Colorado, Aurora

02115

Boston Children's Hospital/Harvard Medical School, Boston

Sponsors
All Listed Sponsors
lead

ACADIA Pharmaceuticals Inc.

INDUSTRY